Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (SYRE)

Historical Holders from Q3 2023 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value
Symbol
SYRE on Nasdaq
Shares outstanding
81,149,970
Price per share
$32.76
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
64,298,633
Total reported value
$1,077,601,498
% of total 13F portfolios
0%
Share change
+600,720
Value change
+$12,200,643
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
135
Price from insider filings
$32.39
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (SYRE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Fairmount Funds Management LLC 10% $136,033,480 8,106,882 Peter Evan Harwin 15 Oct 2025
BlackRock, Inc. 6.6% $58,448,866 3,962,635 BlackRock, Inc. 30 Jun 2025
RTW INVESTMENTS, LP 6.2% $44,260,791 3,621,996 RTW Investments, LP 31 Dec 2024
TANG CAPITAL MANAGEMENT LLC 5.3% $39,104,000 3,200,000 TANG CAPITAL MANAGEMENT, LLC 24 Apr 2025
VANGUARD GROUP INC 5.1% $45,232,144 3,066,586 The Vanguard Group 30 Jun 2025
Venrock Healthcare Capital Partners III, L.P. 4.6% $32,816,175 2,685,448 Venrock Healthcare Capital Partners III, L.P. 31 Dec 2024
PERCEPTIVE ADVISORS LLC 4.4% -56% $31,463,115 -$185,961,697 2,574,723 -80% Perceptive Advisors LLC 31 Dec 2024
As of 30 Sep 2025, Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (SYRE) has 135 institutional shareholders filing 13F forms. They hold 64,298,633 shares. of 81,149,970 outstanding shares (79%) .

Top 25 institutional shareholders own 67% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
FMR LLC 11% 9,060,144 +0.08% 0.01% $151,848,013
Fairmount Funds Management LLC 5% 4,018,101 0% 6.1% $67,343,373
BlackRock, Inc. 4.9% 3,982,744 -0.61% 0% $66,750,788
RTW INVESTMENTS, LP 4.5% 3,621,996 0% 0.75% $60,704,653
TANG CAPITAL MANAGEMENT LLC 3.9% 3,200,000 0% 2.1% $53,632,000
VANGUARD GROUP INC 3.8% 3,050,730 -0.52% 0% $51,130,235
VR ADVISER, LLC 3.3% 2,685,448 0% 2.5% $45,008,108
BRAIDWELL LP 3.2% 2,578,404 0% 1.3% $43,214,051
Capital International Investors 2.9% 2,392,541 0% 0.01% $40,098,987
Driehaus Capital Management LLC 2.5% 2,060,375 -1.2% 0.25% $34,531,885
Commodore Capital LP 2.4% 1,988,084 0% 1.6% $33,320,288
STATE STREET CORP 2.2% 1,785,206 +12% 0% $29,920,053
WELLINGTON MANAGEMENT GROUP LLP 2% 1,640,312 +8.4% 0% $27,491,629
Paradigm Biocapital Advisors LP 1.8% 1,467,266 -22% 0.73% $24,591,378
Affinity Asset Advisors, LLC 1.7% 1,419,299 +134% 2.2% $23,787,451
Jefferies Financial Group Inc. 1.7% 1,388,854 0% 0.21% $23,277,193
PERCEPTIVE ADVISORS LLC 1.5% 1,229,445 -20% 0.6% $20,605,498
GEODE CAPITAL MANAGEMENT, LLC 1.5% 1,225,153 -0.17% 0% $20,536,009
TCG Crossover Management, LLC 1.4% 1,100,582 0.91% $18,445,754
Pictet Asset Management Holding SA 1.3% 1,036,218 -4% 0.02% $17,367,014
BAKER BROS. ADVISORS LP 1.2% 1,000,000 +60% 0.12% $16,760,000
FRANKLIN RESOURCES INC 0.98% 795,275 0% 0% $13,328,809
Polar Capital Holdings Plc 0.97% 788,788 +5.9% 0.06% $13,220,087
PRICE T ROWE ASSOCIATES INC /MD/ 0.76% 620,620 -33% 0% $10,402,000
DEERFIELD MANAGEMENT COMPANY, L.P. 0.76% 613,665 0% 0.16% $10,285,025

Institutional Holders of Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (SYRE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 45,809 $1,500,986 +$768,996 3,276.06% 3
2025 Q3 64,298,633 $1,077,601,498 +$12,200,643 1,676% 135
2025 Q2 63,624,754 $952,552,077 +$19,485,363 1,497% 128
2025 Q1 62,108,053 $1,004,205,173 +$22,237,879 1,613.5% 128
2024 Q4 59,883,954 $1,394,038,663 +$171,656,018 2,328% 129
2024 Q3 51,375,323 $1,511,815,739 +$36,717,611 2,941% 118
2024 Q2 50,386,450 $1,184,304,942 +$421,658,189 2,351% 106
2024 Q1 31,640,426 $1,196,963,610 +$170,619,687 3,793% 101
2023 Q4 28,010,905 $600,997,818 +$524,495,527 2,152% 54
2023 Q3 3,257,983 $39,909,852 +$39,908,455 1,225% 27